Clinical Trials on ALK Fusion Protein Expression in Finland

Total 457 results

Northwell Health
Staten Island University Hospital

Terminated

A Geriatric Home Visit Program to Reduce Post-Hip Fracture Complications

Depression | Infection | Fracture | Gait Instability | Debility

United States
Brown University
James M. Cox Foundation

Completed

Prospective Evaluation of Family Care Rituals in the ICU (FCR)

Depression | Stress Disorders, Post-Traumatic | Anxiety

United States, Italy
UConn Health
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Penn... and other collaborators

Completed

Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians (DREAM)

Depression | Diabetes

United States
Pfizer

Completed

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Hemophilia A

Spain, Finland, Serbia, Georgia, Italy, Romania, Sweden, Turkey, Ukraine
VA Pacific Islands Health Care System
U.S. Army Medical Research and Development Command; University of Hawaii; Pro-Change...

Completed

Computerized Tailored Intervention for Behavioral Sequelae of PTSD in Veterans (CTI-PTSD)

Depression | Smoking | Anxiety | Post Traumatic Stress Disorder

United States
LENZ Therapeutics, Inc
ORA, Inc.

Completed

Phase 3 Evaluation of the Safety and Efficacy of LNZ101 for the Treatment of Presbyopia (CLARITY)

Eye Diseases | Refractive Error | Presbyopia | Miosis | Near Vision

United States
Medtronic Spinal and Biologics
Medtronic Bakken Research Center

Recruiting

The Ailliance Post-Market Clinical Study

Spinal Deformity | Spinal Degenerative Disorder | Spinal Trauma | Spinal Fusion Failure | Spinal Tumor Case

United States
Weill Medical College of Cornell University
National Institute of Mental Health (NIMH)

Completed

Research Evaluating the Value of Augmenting Medication With Psychotherapy (REVAMP)

Depressive Disorder | Depression

United States
Brown University
The Miriam Hospital; Rhode Island Hospital; Spectrum Pharmaceuticals, Inc

Completed

Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma (BRiM)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Lymphoma, B-Cell, Marginal Zone | Waldenstrom Macroglobulinemia | Lymphoma, Small-Cell

United States
Repligen Corporation

Completed

A Study to Assess the Safety, Tolerability and Efficacy of RG2417 in Bipolar I Depression

Bipolar I Depression

United States
Raija Silvennoinen
Takeda; Celgene; Nordic Myeloma Study Group

Active, not recruiting

Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients

Multiple Myeloma

Norway, Sweden, Finland, Lithuania
Brown University
National Institute of Mental Health (NIMH)

Completed

Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss

Major Depressive Disorder | Miscarriage | Stillbirth | Neonatal Death

United States
Sanofi

Completed

Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder (ALBERIO)

Major Depressive Disorder

France, Germany, Turkey, India, Malaysia, Taiwan, Belgium, Tunisia, Finland, Korea, Republic of, Morocco, Greece, Estonia
Butler Hospital
Neuronetics; Providence VA Medical Center

Completed

rTMS for PTSD Comorbid With Major Depressive Disorder

Major Depressive Disorder | Posttraumatic Stress Disorder | Transcranial Magnetic Stimulation, Repetitive

United States
Cervel Neurotech, Inc.

Completed

A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)

Depressive Disorder, Major

United States
Precision BioSciences, Inc.

Recruiting

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Hematologic Malignancy | CD19 Expressing Malignancies

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Embryonal Rhabdomyosarcoma | Fusion-Negative Alveolar Rhabdomyosarcoma | Spindle Cell/Sclerosing Rhabdomyosarcoma

United States, Australia, Canada, New Zealand
European Society for Blood and Marrow Transplantation

Completed

Stem Cell Translpantation in Multiple Myeloma

Multiple Myeloma

Austria, Denmark, Germany, Finland, Canada, Sweden, Norway, France, Italy, United Kingdom, Turkey
Oncotherapeutics
Amgen

Terminated

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Multiple Myeloma

United States
Ancora Bio, Inc. d/b/a EmbarkNeuro, Inc.

Active, not recruiting

ANC-501 in the Treatment of Adults With Major Depressive Disorder

Major Depressive Disorder

United States
Alliance Foundation Trials, LLC.
Pharmacyclics LLC.

Active, not recruiting

Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Multiple Myeloma in Relapse

United States
Wyeth is now a wholly owned subsidiary of Pfizer
Solvay Pharmaceuticals

Completed

Study Evaluating Bifeprunox in Bipolar Depression

Depression Bipolar

United States
Swedish Orphan Biovitrum
ICON plc

Completed

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Hemophilia A

France, Italy, Norway, Sweden, United Kingdom, Austria, Belgium, Finland, Spain
Pfizer
Bristol-Myers Squibb

Recruiting

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

Multiple Myeloma

United States, Canada
Biogen

Completed

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Postpartum Depression

United States
Cephalon

Completed

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

Bipolar I Depression

United States, Bulgaria, Hungary, Romania
AstraZeneca

Completed

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

Bipolar Disorder | Depression, Bipolar

United States
Rhode Island Hospital
National Institute of Neurological Disorders and Stroke (NINDS)

Completed

Treatments for Psychogenic Nonepileptic Seizures (NES) (NES)

Depression | Stress Disorders, Post-Traumatic | Conversion Disorder | Convulsion, Non-Epileptic

United States
Axsome Therapeutics, Inc.

Completed

Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)

Major Depressive Disorder | Treatment Resistant Depression

United States
Axsome Therapeutics, Inc.

Completed

Mechanistic Evaluation of Response in TRD (MERIT) (MERIT)

Major Depressive Disorder | Treatment Resistant Depression

United States
Stichting European Myeloma Network
Pfizer

Recruiting

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma (ERASMM)

Smoldering Multiple Myeloma

Netherlands, France, Italy, Finland, Greece, Norway
LENZ Therapeutics, Inc
ORA, Inc.

Completed

Phase 3 Safety Study for the Treatment of Presbyopia Subjects

Eye Diseases | Presbyopia | Miosis | Near Vision

United States
Forest Laboratories
Gedeon Richter Ltd.

Completed

Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression

Depression, Bipolar

United States, Ukraine, Bulgaria, Canada, Colombia, Russian Federation
AstraZeneca

Terminated

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

Elevated High-sensitivity C-Reactive Protein (hsCRP)

United States, Brazil, Bulgaria, Poland, Russian Federation, South Africa, United Kingdom, Germany, Estonia, Romania, Denmark, Netherlands, Norway, Canada, Mexico, Belgium, Israel, Puerto Rico, Colombia, Argentina, Venezuela, Panama, Urugu... and more
Oncotherapeutics
Takeda

Completed

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Multiple Myeloma

United States
LivaNova

Active, not recruiting

The RECOVER sUb-study, Which Leverages quaNtitative and Credible Research tOols From Verily, Will providE Assessment measuRes for Depressive Episodes (UNCOVER)

Treatment Resistant Depression

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (TRANSFORM-1)

Treatment-resistant Depression

United States, France, Belgium, Mexico, Canada, Brazil, Estonia, Hungary, Slovakia
LivaNova

Recruiting

A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression (RECOVER)

Treatment Resistant Depression

United States
COMPASS Pathways

Recruiting

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Treatment Resistant Depression

United States, Spain, Ireland, France, United Kingdom, Canada, Sweden
Merck Sharp & Dohme LLC

Terminated

Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Treatment Resistant Depression

United States
BlackThorn Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Eli Lilly and Company
Boehringer Ingelheim

Completed

A Randomized Double Blind Study Evaluating Duloxetine in Outpatients With MDD and Pain

Depressive Disorder, Major

Belgium, Germany, France, Slovakia, Czech Republic, Finland
Novo Nordisk A/S

Enrolling by invitation

A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

Haemophilia B

Canada, United Kingdom, Czechia, Germany, Greece, Austria, Belgium, Croatia, Denmark, Finland, Norway, Portugal
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder

Depressive Disorder, Major

Finland, France, South Africa, Estonia, Croatia, Lithuania, Latvia, Slovakia, Poland, Romania
Forest Laboratories

Completed

Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder

Major Depressive Disorder

United States
Institut de Recherches Internationales Servier
ADIR Association

Completed

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

Major Depressive Disorder

Bulgaria, Czechia, Finland, Hungary, Russian Federation, Slovakia, Ukraine
Celgene

Completed

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States, Canada, Germany, Spain, Denmark, Netherlands, Finland, Italy
Alkermes, Inc.

Completed

A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)

Major Depressive Disorder

United States, Canada
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States

Clinical Trials on ALK Fusion Protein Expression in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations